TP53 and cancer: The aforementioned analysis consisted of manual curation of the main and supplementary data, while the latter study, the cancer genome atlas (TCGA) pan‐cancer MPM dataset (n = 86 patients; Hmeljak et al, 2018) available at https://www.cbioportal.org/study/summary?id=meso_tcga_pan_can_atlas_2018 (Cerami et al, 2012), was analyzed in detail, via a systematic query of mutations, copy number alterations, and mRNA and protein expression of KRAS and TP53.